VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
VolitionRx Limited (VNRX) has outlined its strategy to become the global leader in NETs (NETosis) testing through a two-pronged approach. First, the company is in confidential licensing discussions with seven international companies (six valued at nearly $600 billion combined) to launch their Nu.Q® NETs test on existing hospital machines. Second, they're leveraging their CE-marked Nu.Q® NETs test, which has already generated its first revenue in Q1 2025 with nine hospital networks across five European countries implementing the test.
The company estimates the Total Addressable Market for Intensive Care Patients testing alone at $1 billion annually, with potential to exceed $10 billion as applications expand. The Nu.Q® NETs test is being evaluated for multiple clinical applications, including sepsis management, cardiac disease, burns, autoimmune diseases, and pregnancy management. The company's strategy mirrors their successful veterinary market approach, aiming for multiple licensing agreements with ongoing revenue and milestone payments.
VolitionRx Limited (VNRX) ha delineato la sua strategia per diventare il leader mondiale nei test NETs (NETosi) attraverso un approccio a doppio binario. In primo luogo, l'azienda è impegnata in trattative di licenza riservate con sette società internazionali (sei delle quali valutate complessivamente quasi 600 miliardi di dollari) per lanciare il loro test Nu.Q® NETs sulle macchine ospedaliere già esistenti. In secondo luogo, sta sfruttando il test Nu.Q® NETs con marchio CE, che ha già generato i primi ricavi nel primo trimestre del 2025, con nove reti ospedaliere in cinque paesi europei che hanno adottato il test.
L'azienda stima che il mercato totale indirizzabile solo per i pazienti in terapia intensiva raggiunga un valore annuale di 1 miliardo di dollari, con potenziali oltre i 10 miliardi man mano che si espandono le applicazioni. Il test Nu.Q® NETs è in fase di valutazione per molteplici applicazioni cliniche, tra cui la gestione della sepsi, le malattie cardiache, le ustioni, le malattie autoimmuni e la gestione della gravidanza. La strategia aziendale segue l'approccio di successo adottato nel mercato veterinario, puntando a molteplici accordi di licenza con ricavi ricorrenti e pagamenti legati a traguardi.
VolitionRx Limited (VNRX) ha presentado su estrategia para convertirse en el líder global en pruebas de NETs (NETosis) mediante un enfoque doble. Primero, la compañía está en negociaciones confidenciales de licencias con siete empresas internacionales (seis de ellas valoradas en casi 600 mil millones de dólares en conjunto) para lanzar su prueba Nu.Q® NETs en máquinas hospitalarias ya existentes. Segundo, están aprovechando su prueba Nu.Q® NETs con marca CE, que ya generó sus primeros ingresos en el primer trimestre de 2025, con nueve redes hospitalarias en cinco países europeos implementando la prueba.
La empresa estima que el Mercado Total Disponible solo para pruebas en pacientes de cuidados intensivos es de 1.000 millones de dólares anuales, con potencial para superar los 10.000 millones a medida que se amplían las aplicaciones. La prueba Nu.Q® NETs está siendo evaluada para múltiples aplicaciones clínicas, incluyendo manejo de sepsis, enfermedades cardíacas, quemaduras, enfermedades autoinmunes y manejo del embarazo. La estrategia de la empresa refleja su exitoso enfoque en el mercado veterinario, apuntando a múltiples acuerdos de licencia con ingresos recurrentes y pagos por hitos.
VolitionRx Limited (VNRX)는 NETs (NETosis) 검사 분야에서 세계적인 선두주자가 되기 위한 두 가지 접근 방식을 제시했습니다. 첫째, 회사는 7개 국제 기업(그중 6개사는 총 약 6,000억 달러 가치)과 비밀 라이선스 협상을 진행 중이며, 기존 병원 장비에서 Nu.Q® NETs 테스트를 출시할 계획입니다. 둘째, 이미 CE 인증을 받은 Nu.Q® NETs 테스트를 활용하여 2025년 1분기에 첫 수익을 창출했으며, 5개 유럽 국가의 9개 병원 네트워크에서 테스트를 도입했습니다.
회사는 중환자실 환자 검사만으로도 연간 10억 달러의 총 주소 가능 시장(TAM)을 추정하며, 적용 분야가 확대됨에 따라 100억 달러를 초과할 잠재력이 있다고 봅니다. Nu.Q® NETs 테스트는 패혈증 관리, 심장 질환, 화상, 자가면역 질환, 임신 관리 등 다양한 임상 적용을 평가받고 있습니다. 회사의 전략은 수의학 시장에서 성공한 접근법을 반영하며, 지속적인 수익과 마일스톤 지급이 포함된 다수의 라이선스 계약을 목표로 합니다.
VolitionRx Limited (VNRX) a présenté sa stratégie pour devenir le leader mondial des tests NETs (NETose) via une approche en deux volets. Premièrement, la société est en discussions confidentielles de licence avec sept entreprises internationales (dont six valorisées à près de 600 milliards de dollars au total) pour lancer leur test Nu.Q® NETs sur les machines hospitalières existantes. Deuxièmement, elle exploite son test Nu.Q® NETs marqué CE, qui a déjà généré ses premiers revenus au premier trimestre 2025, avec neuf réseaux hospitaliers dans cinq pays européens ayant adopté le test.
L'entreprise estime que le marché total adressable pour les tests des patients en soins intensifs s'élève à 1 milliard de dollars par an, avec un potentiel dépassant les 10 milliards à mesure que les applications se multiplient. Le test Nu.Q® NETs est évalué pour plusieurs applications cliniques, notamment la gestion de la septicémie, les maladies cardiaques, les brûlures, les maladies auto-immunes et la gestion de la grossesse. La stratégie de l'entreprise reflète son approche réussie sur le marché vétérinaire, visant plusieurs accords de licence avec des revenus récurrents et des paiements à l'atteinte d'étapes clés.
VolitionRx Limited (VNRX) hat seine Strategie vorgestellt, um weltweit führend im Bereich NETs (NETose)-Tests zu werden – mit einem zweigleisigen Ansatz. Zum einen führt das Unternehmen vertrauliche Lizenzgespräche mit sieben internationalen Firmen (sechs davon mit einem Gesamtwert von fast 600 Milliarden US-Dollar), um ihren Nu.Q® NETs-Test auf bestehenden Krankenhausgeräten einzuführen. Zum anderen nutzen sie ihren CE-zertifizierten Nu.Q® NETs-Test, der im ersten Quartal 2025 erste Umsätze generierte, da neun Krankenhausnetzwerke in fünf europäischen Ländern den Test implementieren.
Das Unternehmen schätzt den adressierbaren Gesamtmarkt allein für Intensivpatienten-Tests auf 1 Milliarde US-Dollar jährlich, mit Potenzial, über 10 Milliarden US-Dollar zu steigen, wenn die Anwendungen erweitert werden. Der Nu.Q® NETs-Test wird für verschiedene klinische Anwendungen evaluiert, darunter Sepsis-Management, Herzkrankheiten, Verbrennungen, Autoimmunerkrankungen und Schwangerschaftsmanagement. Die Strategie des Unternehmens orientiert sich an ihrem erfolgreichen Vorgehen im Veterinärmarkt und zielt auf mehrere Lizenzvereinbarungen mit laufenden Einnahmen und Meilensteinzahlungen ab.
- None.
- Still in early stages of commercialization with no major licensing deals announced yet
- Revenue generation just beginning, with uncertain growth trajectory
- Dependent on successful partnership negotiations for global expansion
Insights
Volition's NETs test shows revenue traction with CE mark sales and licensing discussions with billion-dollar companies advancing their low-cost commercial strategy.
Volition's commercial update reveals significant momentum in their two-pronged commercialization strategy for their Nu.Q® NETs diagnostic platform. The company has achieved a critical milestone by recording first revenues from their CE-marked NETs test in Q1 2025, with nine hospital networks across five countries already placing orders. Their customer pipeline appears robust, with twelve additional hospital networks in discussions and nine evaluations expected in H2 2025.
The licensing strategy demonstrates impressive traction with seven international companies in discussions, six having a combined market capitalization near $600 billion. Several potential partners have already completed technology transfer to their platforms - a crucial technical validation step before commercial agreements. Volition's approach mirrors their successful veterinary market strategy: leveraging partners' existing infrastructure to minimize capital and operational expenditures while capturing recurring revenue through component supply and IP licensing.
The business model is particularly compelling as it provides Volition's partners with new revenue streams from their existing installed base without significant additional investment. The addressable market opportunity is substantial, with ICU patient monitoring alone representing a $1 billion annual opportunity, and potential applications across multiple clinical areas potentially exceeding $10 billion annually.
What's most notable is the breadth of clinical applications being evaluated by hospital networks - ranging from sepsis management (the largest opportunity) to cardiac issues, autoimmune diseases, transplant monitoring, and pregnancy management. This diversity of applications reduces commercial risk through multiple potential revenue streams rather than dependence on a single indication.
While revenue materiality remains modest at this stage, the combination of first commercial sales, advanced licensing discussions, and successful technology transfers represents meaningful commercial validation for Volition's long-developed technology.
A Message from our Chief Commercial Officer
As was stated in our shareholder update recently, 2025 is a pivotal year for Volition as we focus on commercializing our groundbreaking Nu.Q® platform in the human diagnostics market. Today, I would like to focus on the large, and very broad Nu.Q® NETs (NETosis) opportunity.
Our efforts on this are two-pronged:
1. Licensing
To negotiate with large multi-national companies to launch our Nu.Q® NETs test on their extensive base of installed machines already servicing every hospital in the world, with existing labs and sales teams. The focus of these discussions is centered around significant unmet needs in sepsis and coagulation. The aim, as we successfully achieved in the vet space, is to operate a low CapEx / low OpEx model; Low CapEx for our partners in that they already have a global footprint of their automated systems and low OpEx for Volition as the majority of functions (sales, regulatory and clinical affairs, sales, marketing) are conducted by our partners. Volition simply provides access to its intellectual property and the supply of key components for the test itself. We believe this is a win-win for everyone, allowing broad adoption worldwide with limited investment and giving these large companies a new revenue stream from their installed base.
I am delighted to report we are in confidential discussions regarding the licensing and supply of our Nu.Q® NETs assay with seven international companies. Notably, the combined market value of six of these companies is just under
We are making significant headway in the commercialization of Nu.Q® NETs. Licensing discussions are progressing well with several potential licensing companies having already successfully completed the tech transfer of our assay onto their platform(s). Our goal is to secure multiple licensing agreements in the human diagnostics space, mirroring our successful strategy in the veterinary market, with diverse deal structures, all with ongoing revenue and some to include large milestone payments. Volition's technology has already been successfully transferred and run on several other companies' analyzers.
Our strong clinical evidence supports the use of our Nu.Q® NETs technology in a critical area, sepsis. The Total Addressable Market for the testing and monitoring of Intensive Care Patients alone represents a
2. Leverage existing CE-marked Nu.Q® NETs test
The second prong of our strategy is to leverage our granted CE mark, approved in the EU for any NETs related diseases. As a reminder, Volition's chemiluminescent immunoassay (ChLIA) version of the CE-marked Nu.Q® NETs Test is via the IDS-i10™ automated analyzer platform from Immunodiagnostic Systems, a subsidiary of Revvity. I would like to thank Immunodiagnostic Systems for their collaborative approach. Our aim is to sell this product, either directly or in conjunction with Immunodiagnostic Systems, to institutions for use in the very wide range of clinical applications where NETosis plays a critical role.
In a significant commercial milestone, we recorded our first revenue from sales of our CE-Marked Nu.Q® NETs automated product in
The range of potential clinical use cases where NETosis plays a role is extremely broad, equating to a mix of potential market sizes (from small to very large); there is clearly wide unmet clinical needs driving these evaluations.
NETs are a key part of a broad range of clinical conditions, and our aim is to become the "NETs company" worldwide, by partnering with the very best companies, hospital networks and governments. The level interest in using our Nu.Q® NETs test is notable: clinical use cases include coagulation, cardiac issues, renal disease, trauma, burns, auto immune diseases, organ transplant, pregnancy management and of course the biggest being Sepsis.
We expect, through this second prong that our Nu.Q® NETs test will start to be used in routine clinical practice with patients next year in the EU and then expanded to use worldwide through the expected global licensing agreements of the first prong to our strategy. This is a great outcome for Volition; they buy kits, generating not only revenue but also clinical data for a wide range of use cases.
We look forward to updating you in the exciting months ahead.
Clinical Applications Under Evaluation by Centers of Excellence in |
Sepsis patient management |
Treatment monitoring of sepsis patients (EMBRACE trial NCT06694701) |
Sepsis associated Acute Kidney Injury prediction |
Follow-up of discharged patients from ICU |
Burns |
Distinction between SIRS and sepsis patients |
Cardiac disease x 2 centers |
Cardiopathy post surgery patient management |
Acute brain injury |
Anaphylactic shock during anesthesia |
Lung post-transplant patient management |
Autoimmune diseases such as Systemic Lupus Erythematosus, Rheumatoid Arthritis |
NETosis in synovial fluid for Rheumatoid Arthritis |
Potential Clinical Applications in Discussion |
Burns |
Distinction between SIRS and sepsis patients |
Sepsis patient management x 6 centers |
Pediatric sepsis management |
Pregnancy management x2 centers |
Inflammatory conditions |
- Combined stock market valuation as of 15th April 2025, data on file
- Data on file, Volition Total Addressable Market Model
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations:
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of
View original content:SOURCE VolitionRx Limited
FAQ
What is the market potential for VNRX's Nu.Q® NETs test?
How many companies is VolitionRx in licensing discussions with for Nu.Q® NETs?
What clinical applications is VNRX's Nu.Q® NETs test being evaluated for?
Has VNRX started generating revenue from Nu.Q® NETs test?
How many hospitals are currently using VNRX's Nu.Q® NETs test?
